Gapping down
In reaction to disappointing earnings/guidance: NX -0.7%, .
M&A news: NWL -5.2% (Jarden to be acquired by Newell Rubbermaid (NWL) for $60.00/share), PBY -0.9% (Pep Boys and Bridgestone (BRDCY) amended terms to merger agreement from $15.00 per share to $15.50 per share in cash)
Select metals/mining stocks trading lower: HMY -9.9%, AU -7.2%, MT -3.3%, BP -2.2%, BBL -2.2%, SLV -2%, ABX -1.5%, SLW -1.4%, FCX -1.4%, GDX -1.1%, GG -0.9%
Select oil/gas related names showing early weakness: SDRL -7.9%, BHI -4.9%, SWN -3.6%, CHK -3.1%, RDS.A -2.2%, RIG -2.1%, PBR -2%
Other news: ATRA -36.7% (announces that its Phase 2 proof-of-concept clinical trial for PINTA 745 did not meet its primary endpoint), BIND -11.3% (reports that the NSCLC Cohort of the Phase 2 INSITE 1 trial will advance to the second stage; the KRAS mutant NSCLC arm will not advance to the second stage), PSTI -9.2% (still checking), ECA -4.8% (decreases annualized 2016 dividend by $0.26/share to $0.06/share), SYT -3.8% (still checking), SYT -3.8% (may be related to no announcement of M&A deal over the weekend)
Analyst comments: GPRO -5.3% (downgraded to Underweight from Equal-Weight at Morgan Stanley), GTE -5% (downgraded to Neutral from Buy at Citigroup), AAPL -1.7% (hearing Morgan Stanley substantially lowering iPhone estimates), HRL -1.6% (downgraded to Hold at Deutsche Bank), DD -1.5% (downgraded to Hold from Buy at Jefferies), SYK -0.8% (downgraded to Underperform from Market Perform at BMO Capital)
In reaction to disappointing earnings/guidance: NX -0.7%, .
M&A news: NWL -5.2% (Jarden to be acquired by Newell Rubbermaid (NWL) for $60.00/share), PBY -0.9% (Pep Boys and Bridgestone (BRDCY) amended terms to merger agreement from $15.00 per share to $15.50 per share in cash)
Select metals/mining stocks trading lower: HMY -9.9%, AU -7.2%, MT -3.3%, BP -2.2%, BBL -2.2%, SLV -2%, ABX -1.5%, SLW -1.4%, FCX -1.4%, GDX -1.1%, GG -0.9%
Select oil/gas related names showing early weakness: SDRL -7.9%, BHI -4.9%, SWN -3.6%, CHK -3.1%, RDS.A -2.2%, RIG -2.1%, PBR -2%
Other news: ATRA -36.7% (announces that its Phase 2 proof-of-concept clinical trial for PINTA 745 did not meet its primary endpoint), BIND -11.3% (reports that the NSCLC Cohort of the Phase 2 INSITE 1 trial will advance to the second stage; the KRAS mutant NSCLC arm will not advance to the second stage), PSTI -9.2% (still checking), ECA -4.8% (decreases annualized 2016 dividend by $0.26/share to $0.06/share), SYT -3.8% (still checking), SYT -3.8% (may be related to no announcement of M&A deal over the weekend)
Analyst comments: GPRO -5.3% (downgraded to Underweight from Equal-Weight at Morgan Stanley), GTE -5% (downgraded to Neutral from Buy at Citigroup), AAPL -1.7% (hearing Morgan Stanley substantially lowering iPhone estimates), HRL -1.6% (downgraded to Hold at Deutsche Bank), DD -1.5% (downgraded to Hold from Buy at Jefferies), SYK -0.8% (downgraded to Underperform from Market Perform at BMO Capital)